AVXL News & Events

Anavex Life Sciences announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. Dr. Paeger currently serves as Chief Executive Officer of the AMEOS Group

Latest data shows the largest indicative borrow rate increases among liquid option names include: ARK Innovation ETF (ARKK) 7.73% +4.99, Defiance Daily Target 2X Long RGTI ETF (RGTX) 31.00% +1.81, Canopy Growth (CGC) 25.57% +0.70, DeFi Development Corp (DFDV) 18.56% +0.69, Anavex (AVXL) 3.99% +0.46, Serve Robotics Inc (SERV) 5.52% +0.40, - USA Rare Earth Inc (USAR) 9.93% +0.40, Sealsq Corp (LAES) 46.02% +0.34, Newmont Mining (NEM) 0.55% +0.30, and T-REX 2X LONG NVIDIA DAILY (NVDX) 9.89% +0.29.

"As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral blarcamesine in early Alzheimer's disease. Based on our commitment to improving the lives of patients with neurological disorders, we remain excited about the therapeutic potential of oral blarcamesine. We look forward to working with the regulatory agencies in Europe and the U.S. to advance oral blarcamesine as a potential new treatment option for patients." said Christopher U. Missling, PhD, President and CEO of Anavex. "An estimated 7.2 million people in the U.S. and 7 million in Europe are living with Alzheimer's disease. Our mission is to develop targeted, orally delivered therapies aimed at a range of CNS related diseases, and specifically early-stage Alzheimer's, where intervention may have the greatest impact."

Update on regulatory pathway for blarcamesine in early Alzheimer's disease; Progress on clinical development program in Parkinson's disease through targeted approach, potentially addressing the highest disease burden in Parkinson's disease; Regulatory and clinical trial update for blarcamesine in Parkinson's disease; Regulatory and clinical trial update for blarcamesine in Rett syndrome; Fragile X development update: Design of Phase 2/3 clinical trial; Advancing ANAVEX 3-71 towards pivotal clinical studies for the treatment of schizophrenia related disorders; Progressing collaborative initiatives and strategic partnership activities; New scientific findings to be presented at upcoming conferences or publications: Oral Presentation at 16th Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity, to be held on March 10-12, 2026 at Johns Hopkins University Bloomberg Center Washington, D.C.: "Exploring Treatment for Older Adults with Pre-Frailty to Mitigate Cognitive and Physical Decline Targeting Autophagy with Oral Blarcamesine"; Clinical relationship with biomarker: Correlation between clinical endpoints and reduced brain region atrophy with blarcamesine in early Alzheimer's disease; Publication Alzheimer's disease: Precision Medicine ABCLEAR populations of the ANAVEX 2-73-AD-004 Phase 2b/3 trial; Publication Alzheimer's disease: Precision Medicine gene, COL24A1, with estimated greater than70% prevalence in the early AD population has the potential to establish effective treatment of early Alzheimer's disease through effectiveness of autophagy-enhancing blarcamesine; Publication Fragile X: Blarcamesine corrects EEG biomarkers of cortical dysfunction in a mouse model of fragile X syndrome.